Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TiGenix NV

Division of Takeda Pharmaceutical Co. Ltd.
www.tigenix.com

Latest From TiGenix NV

Japan 2010s In Review: Specialize, Focus, Innovate

Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.

Japan Reimbursement

Japan 2010s In Review: Specialize, Focus, Innovate

Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.

Japan Business Strategies

Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy

Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.

Research & Development India

BIO 2019 Notebook: Sharpless On Pricing, Marks On Gene Therapy, Takeda On M&A

News and views from day two of the BIO International Convention: US FDA's Sharpless decries the focus on the price of "medical miracle" Zolgensma; CBER Director Marks talks about how his division will staff up to review cell and gene therapy candidates; and Takeda explains why its business development philosophy leads to the valuation seen in the Ariad buyout.

Pricing Debate Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Eduardo Bravo, Mng. Dir. & CEO
    Claudia D’Augusta, CFO
    Wilfried Dalemans, CTO
    Marie Paule Richard, MD, CMO
  • Contact Info
  • TiGenix NV
    Phone: (32) 16 39 60 60
    Romeinse Straat 12, Bus 2
    Leuven, B-3001
    Belgium
UsernamePublicRestriction

Register